We are live on ! Find out more
CNTA

Centessa Pharmaceuticals
CNTA

Delisted

CNTA was delisted on the 23rd of June, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in Centessa Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 159 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 161 → 0 (-161)

100% less funds holding in top 10

Funds holding in top 10: 16 → 0 (-16)

100% less capital invested

Capital invested by funds: $5.9B → $0 (-$5.9B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 159

100.55% less ownership

Funds ownership: 100.55% → 0% (-101%)

Holders
–
Holders Change
-161
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-16
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
159
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MVM
Medicxi Ventures Management
Jersey
-$793M
2
ACA
Avoro Capital Advisors
New York
-$454M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$355M
4
PCM
Pentwater Capital Management
Florida
-$325M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$272M

CNTA Hedge Fund Activity: Q2 2026 in Review

0 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2026, worth a combined $0 — down 100% from $5.9B a quarter earlier.

Sellers outnumbered buyers: 159 funds closed out of CNTA and 0 opened new positions — a net loss of 159 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $793M sold.

  • 0 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2026, down from 161 in Q1 2026.
  • Funds reported $0 of Centessa Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Centessa Pharmaceuticals positions in Q2 2026 and 159 closed out, a net change of -159 holders.
  • The largest Centessa Pharmaceuticals seller in Q2 2026 was Medicxi Ventures Management, an estimated $793M sold.

Based on aggregated 13F filings for Q2 2026.